AR002270A1 - Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina - Google Patents

Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina

Info

Publication number
AR002270A1
AR002270A1 ARP960101082A AR10108296A AR002270A1 AR 002270 A1 AR002270 A1 AR 002270A1 AR P960101082 A ARP960101082 A AR P960101082A AR 10108296 A AR10108296 A AR 10108296A AR 002270 A1 AR002270 A1 AR 002270A1
Authority
AR
Argentina
Prior art keywords
purin
dihydro
oxo
ethyl
amino
Prior art date
Application number
ARP960101082A
Other languages
English (en)
Spanish (es)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of AR002270A1 publication Critical patent/AR002270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ARP960101082A 1995-01-20 1996-01-19 Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina AR002270A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
AR002270A1 true AR002270A1 (es) 1998-03-11

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101082A AR002270A1 (es) 1995-01-20 1996-01-19 Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina

Country Status (40)

Country Link
US (1) US6107302A (2)
EP (1) EP0804436B1 (2)
JP (1) JP3176633B2 (2)
KR (1) KR100376074B1 (2)
CN (1) CN1049893C (2)
AP (1) AP662A (2)
AR (1) AR002270A1 (2)
AT (1) ATE302777T1 (2)
AU (1) AU702794B2 (2)
BG (1) BG63393B1 (2)
BR (1) BR9606768A (2)
CA (1) CA2210799C (2)
CY (1) CY2531B1 (2)
CZ (1) CZ297065B6 (2)
DE (1) DE69635106T2 (2)
DK (1) DK0804436T3 (2)
EA (1) EA000364B1 (2)
EE (1) EE03528B1 (2)
ES (1) ES2248806T3 (2)
FI (1) FI973063L (2)
GB (1) GB9501178D0 (2)
GE (1) GEP20001940B (2)
HR (1) HRP960024B1 (2)
HU (1) HU222993B1 (2)
IL (1) IL116831A (2)
IN (1) IN182468B (2)
IS (1) IS2268B (2)
NO (1) NO315558B1 (2)
NZ (1) NZ298851A (2)
OA (1) OA10499A (2)
PL (1) PL182175B1 (2)
RO (1) RO118693B1 (2)
RS (1) RS49518B (2)
SI (1) SI0804436T1 (2)
SK (1) SK285329B6 (2)
TR (1) TR199700656T1 (2)
UA (1) UA46001C2 (2)
UY (1) UY25779A1 (2)
WO (1) WO1996022291A1 (2)
ZA (1) ZA96449B (2)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ATE254463T1 (de) * 1996-01-19 2003-12-15 Glaxo Group Ltd Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
EP0976750A4 (en) * 1997-01-17 2001-05-30 Ajinomoto Kk NEW Z-VALACYCLOVIR CRYSTALS
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
EP1436295A4 (en) * 2001-09-07 2007-07-11 Teva Pharma CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2649826A1 (en) * 2001-11-14 2003-05-22 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
ATE335743T1 (de) * 2002-10-16 2006-09-15 Teva Pharma Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
EP1638972A2 (en) * 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
MXPA06008197A (es) * 2004-01-21 2007-04-02 Teva Pharma Proceso para la preparacion de clorhidrato de valaciclovir.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1761535A1 (en) * 2004-06-30 2007-03-14 Teva Pharmaceutical Industries Ltd Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ES2157259T3 (es) * 1993-06-10 2001-08-16 Rolabo Sl Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos.
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
HU222993B1 (hu) 2004-01-28
CN1179159A (zh) 1998-04-15
CY2531B1 (en) 2006-04-12
KR100376074B1 (ko) 2003-06-02
AP662A (en) 1998-08-19
HRP960024B1 (en) 2005-08-31
PL182175B1 (pl) 2001-11-30
DK0804436T3 (da) 2005-12-27
EP0804436B1 (en) 2005-08-24
CA2210799A1 (en) 1996-07-25
EE03528B1 (et) 2001-10-15
EA199700124A1 (ru) 1997-12-30
OA10499A (en) 2002-04-10
MX9705462A (es) 1997-10-31
DE69635106D1 (de) 2005-09-29
EE9700175A (et) 1998-02-16
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
NZ298851A (en) 1999-01-28
FI973063A7 (fi) 1997-09-18
HRP960024A2 (en) 1997-10-31
JP3176633B2 (ja) 2001-06-18
IL116831A0 (en) 1996-05-14
PL321326A1 (en) 1997-12-08
AU702794B2 (en) 1999-03-04
ATE302777T1 (de) 2005-09-15
TR199700656T1 (xx) 1998-03-21
BR9606768A (pt) 1997-12-30
SI0804436T1 (sl) 2006-02-28
YU3396A (sh) 1998-12-23
BG101833A (bg) 1998-04-30
RO118693B1 (ro) 2003-09-30
DE69635106T2 (de) 2006-06-08
IL116831A (en) 1998-10-30
NO973326L (no) 1997-09-16
US6107302A (en) 2000-08-22
KR19980701525A (ko) 1998-05-15
NO315558B1 (no) 2003-09-22
CA2210799C (en) 2008-06-10
SK96597A3 (en) 1998-02-04
GEP20001940B (en) 2000-02-05
AP9701058A0 (en) 1997-10-31
IS4527A (is) 1997-07-15
GB9501178D0 (en) 1995-03-08
ES2248806T3 (es) 2006-03-16
NO973326D0 (no) 1997-07-18
EP0804436A1 (en) 1997-11-05
CZ297065B6 (cs) 2006-08-16
UY25779A1 (es) 2000-08-21
RS49518B (sr) 2006-10-27
ZA96449B (en) 1996-08-07
IN182468B (2) 1999-04-17
HUP9801836A2 (hu) 1999-05-28
WO1996022291A1 (en) 1996-07-25
FI973063L (fi) 1997-09-18
UA46001C2 (uk) 2002-05-15
EA000364B1 (ru) 1999-06-24
JPH11503718A (ja) 1999-03-30
SK285329B6 (sk) 2006-11-03
HUP9801836A3 (en) 1999-06-28
AU4453996A (en) 1996-08-07
FI973063A0 (fi) 1997-07-18
CZ229497A3 (en) 1997-12-17
IS2268B (is) 2007-07-15

Similar Documents

Publication Publication Date Title
FI973063A7 (fi) Guaniinijohdannainen
AR038430A2 (es) Derivados de parahercuamida b
FI925737A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten indol-3-yylialkyylipiperatsiinijohdannaisten valmistamiseksi
SE9904505D0 (sv) Novel compounds
ITMI931714A0 (it) Uso del taxol per la produzione di un medicamento per il trattamento delle forme cancerose
FI914905L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten merkaptoasetyyliamidopyrrolo- ja -pyridobentsatsepiinijohdannaisten valmistamiseksi
BR0017030A (pt) Derivados de tiazolilamida
UY26782A1 (es) Derivados del benzotiazol
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
CA2046755A1 (en) /2r/-2-[di/2-propyl/phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use
YU63696A (sh) Novi fenilamidin-derivati, postupci za njihovo pripremanje i njihova primena kao lekova
KR920700625A (ko) 고혈압 치료를 위한 신장에 선택적인 프로드러그(Prodrug)
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
IL138288A0 (en) Process for the production of purine derivatives and intermediates thereof
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
MY127470A (en) Process for the synthesis of chloropurine intermediates
FI103202B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-sulfonamido-1,4-dihydrokinoliiinijohdannaisten valmistamiseksi
FI905930A7 (fi) Menetelmä uusien, farmakologisesti käyttökelpoisten bispilokarpiinihapon esterijohdannaisten valmistamiseksi
ES2062214T3 (es) Derivados de aminooligohidroxi inhibidores de renina.
HU9203928D0 (en) 6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them
FI912733L (fi) Menetelmä terapeuttisesti käyttökelpoisten /(1-aryylipyrrolidin-2-yyli)metyyli/piperatsiinijohdannaisten valmistamiseksi
SE9704834D0 (sv) New process
AU6248790A (en) Process for the preparation of 2-(2-furyl)ethanol amine

Legal Events

Date Code Title Description
FC Refusal